Sherry Korczynski - 09 Mar 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role: Chief Commercial Officer
Signature: /s/ Lori Braender, as Attorney-In-Fact
Issuer symbol: AQST
Transactions as of: 09 Mar 2026
Net transactions value: -$65,687
Form type: 4
Filing time: 11 Mar 2026, 12:51:23 UTC
Previous filing: 15 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Korczynski Sherry	Chief Commercial Officer	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN	/s/ Lori Braender, as Attorney-In-Fact	11 Mar 2026	0002026090

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AQST	Common Stock	Award		+75,000	+41%	$0.000000^*	256,858	09 Mar 2026	Direct	F1
transaction	AQST	Common Stock	Sale	$65,687	-15,741	-6.1%	$4.17	241,117	10 Mar 2026	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AQST	Non-Qualified Stock Option (right to buy)	Award		+42,500		$4.29^*	42,500	09 Mar 2026	Common Stock	42,500	$4.29	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4	The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.